Xia Zhang
School of Life Science and Technology
ShanghaiTech University
Zhang Xiang is a Ph.D. in the State Key Laboratory of Solid-State Lighting, Institute of Semiconductors, Chinese Academy of Sciences. Her research interests focus on GaN epitaxial growth on novel substrate and LED device fabrications, including growth on graphene and β-Ga2O3. During her PhD, she experimentally and theoretically studied the mechanism of nucleation of AlN on oxygen-deficiency graphene substrates. Furthermore, she also investigated the epitaxy method of high-quality GaN films onβ-Ga2O3 substrate and she creatively proposed to grow GaN pyramid directly onβ-Ga2O3 substrate by selective growth.
Lung-protective Ventilation in Patients with Brain Injury: A Multicenter Cross-sectional Study and Questionnaire Survey in China.
Chinese medical journal Jul, 2016 | Pubmed ID: 27411450
CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer.
Oncotarget Nov, 2016 | Pubmed ID: 27801665
Assessment of Tear Film and Bulbar Redness by Keratograph 5M in Pediatric Patients After Orthokeratology.
Eye & contact lens Nov, 2018 | Pubmed ID: 29554029
[Expression profiles of microRNA in peripheral blood mononuclear cells and immune factors in pregnant women with hepatitis B virus infection].
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics Aug, 2019 | Pubmed ID: 31400127
p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report.
BMC neurology Mar, 2020 | Pubmed ID: 32126984
Anti-fibrosis potential of pirarubicin via inducing apoptotic and autophagic cell death in rabbit conjunctiva.
Experimental eye research 11, 2020 | Pubmed ID: 32896532
A Case Report: Cutaneous Metastasis of Advanced Rectal Cancer with BRAF Mutation.
OncoTargets and therapy , 2021 | Pubmed ID: 33603403
The Associations of Lymphocyte Ratio and Neutrophil Ratio on Liver Dysfunction in COVID-19 Patients.
Frontiers in immunology , 2021 | Pubmed ID: 34552588
Competing Nomogram for Late-Period Breast Cancer-Specific Death in Patients with Early-Stage Hormone Receptor-Positive Breast Cancer.
Clinical breast cancer 04, 2022 | Pubmed ID: 34627728
Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer.
International journal of clinical oncology Jul, 2022 | Pubmed ID: 35397755
In Vitro Biochemical Assays using Biotin Labels to Study Protein-Nucleic Acid Interactions
Lina Yu*,1,
Wenxiu He*,1,
Jie Xie*,1,
Rui Guo*,1,
Juan Ni2,
Xia Zhang3,
Quishi Xu1,
Caifeng Wang1,
Qiuling Yue1,
Fangfang Li1,
Mengcheng Luo4,
Bo Sun3,
Lan Ye1,
Ke Zheng1
1State Key Laboratory of Reproductive Medicine, Nanjing Medical University,
2, The Affiliated Hospital of Hangzhou Normal University,
3School of Life Science and Technology, ShanghaiTech University,
4Department of Tissue and Embryology, School of Basic Medical Sciences, Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University
An R-Based Landscape Validation of a Competing Risk Model
Haiping Lin*,1,3,
Hongjuan Zheng*,2,
Chenyang Ge3,
Lixian Ling2,
Ruihua Yin2,
Qinghua Wang2,
Xia Zhang2,
Shishi Zhou2,
Xiayun Jin2,
Xifeng Xu2,
Jianfei Fu2
1Department of Hepatobiliary Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine,
2Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine,
3Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有，本公司不涉及任何医疗业务和医疗服务。